Our May Omics Series discussion group focused on the current uses and potential of multi-omics bioinformatics.

Our April 2022 Omics Series discussion group focused on the potential and future of single-cell proteomics.

Showcasing the highlights from NextGen Omics: In-Person 2022. We asked Alex Tamburino, Associate Principal Scientist at Merck about his experience at the event.

In Conversation With Theodore Alexandrov, Team Leader, European Molecular Biology Laboratory

Gábor Balázsi, Henry Laufer Professor of Physical and Quantitative Biology at Stony Brook University, takes us through the most valuable features that NextGen Omics US brought us in 2022.

In this Commentary article, we investigate the application of new research techniques to inspecting genomic data for the presence of de novo variants - genetic alterations present for the first time in one individual as a result of a variant inherited from a parent. Used in combination with data from the 100,000 Genome Project, these techniques could reduce the time taken for patients to receive a diagnosis for rare genetic diseases.

Rebus Biosystems has assembled five collaborators to share aspects of their cellular examinations of the human brain. From new strides in understanding brain development to exploring the sub cellular details of disease, these presentations illustrate the array of knowledge gained through cellular spatial exploration.

This month’s discussion was led by Pieter van der Velden. Topics included improving multiplex assays, T-Cell quantification and DNA methylation.

Single-cell proteomics has developed quickly, despite being a relatively new field. NanoPOTS and FACS are being used to improve proteome coverage and minimise sample size.

At NGO US: In-Person 2022, Carlos Cruchaga of the Washington School of Medicine presents on using QTL and GWAS data to unlock the future of therapeutic treatment for neurodegenerative disease.